SCHEMBL20138374

SCHEMBL20138374

CCCN1C(=O)/C(=N\C(=O)N(C)C)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.51
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH2 P05091 1/20 0.45
ALDH3A1 P30838 1/20 0.45
CDC25A P30304 10/20 0.44
CES1 P23141 3/20 0.44
DRD2 P14416 1/20 0.43
HTR6 P50406 1/20 0.43
BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18189117 1.00 ACE (0.51) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18189167 0.89 ALDH1A1 (0.51) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18189165 0.89 ALDH1A1 (0.51) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18189123 0.84 PDE5A (0.43) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL20138381 0.84 PDE5A (0.43) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18200162 0.83 ACE (0.52) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18189107 0.83 ACE (0.52) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL18189109 0.83 ACE (0.52) ACEALDH1A1KDM4ELMNAKMT2A
SCHEMBL20138372 0.83 CA12 (0.52) ACEALDH1A1LMNAKMT2ACA12
SCHEMBL20138371 0.83 CA12 (0.52) ACEALDH1A1LMNAKMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288933-B1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUND FOR RES DEV (US) 2021-10-06 EP disclosed
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-06 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof PARK7, OPRK1, COMT ACE 1563/4885ALDH1A1 212/4885KDM4E 2634/4885
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PARK7, OPRK1, COMT ACE 1563/4885ALDH1A1 212/4885KDM4E 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.